See more : Dr. Martens plc (DOCS.L) Income Statement Analysis – Financial Results
Complete financial analysis of Genprex, Inc. (GNPX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Genprex, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Imricor Medical Systems, Inc. (IMR.AX) Income Statement Analysis – Financial Results
- China Merchants Energy Shipping Co., Ltd. (601872.SS) Income Statement Analysis – Financial Results
- Nova Minerals Limited (NVA) Income Statement Analysis – Financial Results
- Epiroc AB (publ) (EPOKY) Income Statement Analysis – Financial Results
- O Sorbet D’amour SA (MLOSA.PA) Income Statement Analysis – Financial Results
Genprex, Inc. (GNPX)
About Genprex, Inc.
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 15.00K | 23.83M | 22.53K | 22.78K | 13.07K | 5.89K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -15.00K | -23.83M | -22.53K | -22.78K | -13.07K | -5.89K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 17.62M | 11.51M | 8.61M | 7.30M | 1.97M | 971.43K | 289.93K | 354.88K | 201.96K |
| General & Administrative | 13.44M | 12.30M | 10.97M | 10.64M | 8.70M | 11.39M | 3.02M | 3.78M | 865.70K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.44M | 12.30M | 10.97M | 10.64M | 8.70M | 11.39M | 3.02M | 3.78M | 865.70K |
| Other Expenses | 0.00 | 25.58K | 22.53K | 22.78K | 13.07K | 5.89K | 3.24K | 0.00 | 0.00 |
| Operating Expenses | 31.06M | 23.83M | 19.60M | 17.96M | 10.68M | 12.36M | 3.31M | 4.13M | 1.07M |
| Cost & Expenses | 31.08M | 23.83M | 19.60M | 17.96M | 10.68M | 12.36M | 3.31M | 4.13M | 1.07M |
| Interest Income | 215.11K | 90.10K | 5.13K | 18.81K | 27.91K | 29.18K | 80.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 37.98K | 1.89K | 0.00 | 0.00 |
| Depreciation & Amortization | 15.00K | 25.58K | 22.53K | 22.78K | 13.07K | 5.89K | 3.24K | 862.00 | 2.06K |
| EBITDA | -31.06M | -23.81M | -20.65M | -17.94M | -10.64M | -12.33M | -3.31M | -4.13M | -1.07M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -31.08M | -23.83M | -19.60M | -17.96M | -10.68M | -12.36M | -3.31M | -4.13M | -1.07M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 215.11K | 90.10K | 5.13K | 18.81K | 27.90K | -8.80K | -1.81K | 0.00 | 0.00 |
| Income Before Tax | -30.86M | -23.74M | -19.60M | -17.94M | -10.65M | -12.37M | -3.31M | -4.13M | -1.07M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 5.72M | -5.13K | -18.81K | -130.89K | 29.18K | 80.00 | 0.00 | 0.00 |
| Net Income | -30.86M | -29.46M | -19.59M | -17.92M | -10.65M | -12.37M | -3.31M | -4.13M | -1.07M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -22.58 | -24.59 | -16.64 | -20.18 | -26.64 | -35.97 | -11.55 | -15.30 | -23.25 |
| EPS Diluted | -22.56 | -24.58 | -16.64 | -20.18 | -26.59 | -35.94 | -11.53 | -15.26 | -22.93 |
| Weighted Avg Shares Out | 1.37M | 1.20M | 1.18M | 888.00K | 400.00K | 344.00K | 287.00K | 270.00K | 46.00K |
| Weighted Avg Shares Out (Dil) | 1.37M | 1.20M | 1.18M | 888.07K | 400.68K | 344.28K | 287.50K | 270.87K | 46.66K |
GNPX Stock: 5 Things to Know as Genprex Rockets Higher
Shares of GNPX stock are soaring higher after the FDA granted fast track designation (FTD) for the company's lead drug candidate, REQORSA. The post GNPX Stock: 5 Things to Know as Genprex Rockets Higher appeared first on InvestorPlace.
8 Top Penny Stocks to Watch Today: EVGRF, PTE, BLCT, GNPX, AFI, CELZ, AUVI, WAVE
We're diving into the top penny stocks to watch today as several names in the space see major movement on Monday alongside heavy trading. The post 8 Top Penny Stocks to Watch Today: EVGRF, PTE, BLCT, GNPX, AFI, CELZ, AUVI,...
Why Genprex Shares Are Soaring Today
Genprex Inc (NASDAQ: GNPX) is trading higher Monday after the company announced it received U.S. Food and Drug Administration Fast Track Designation (FTD) for REQORSA Immunogene Therapy in combination with Merck & Co Inc's (NYSE: MRK) Keytruda for the treatment of non-small cell...
Genprex targets non-small cell lung cancer and diabetes via gene therapy
Focused on developing life-changing therapies for patients with cancer and diabetes Advancing lead product REQORSA immunogene therapy for non-small cell lung cancer Struck licensing agreement with the University of Pittsburgh for diabetes gene therapy What Genprex does: Genprex Inc (NASDAQ:GNPX) is...
Genprex wins Fast Track designation for REQORSA in combo with Keytruda for treating Non-Small Cell Lung Cancer from FDA
Genprex, Inc. (NASDAQ:GNPX) revealed that the US Food and Drug Administration (FDA) granted Fast Track designation to the company's lead drug candidate, REQORSA Immunogene Therapy, in combination with Merck & Co Inc (NYSE:MRK)'s Keytruda in patients with stage III or IV...
Genprex's Lead Cancer Program Scores Second FDA Fast Track Tag For Lung Cancer Setting
The FDA has granted Fast Track Designation for Genprex Inc's (NASDAQ: GNPX) lead drug candidate, Reqorsa Immunogene combination therapy. The designation covers Reqorsa combined with Merck & Co Inc's (NYSE: MRK) Keytruda for unresectable stage III or IV non-small cell lung cancer (NSCLC) whose...
Genprex: Limited Clinical Data To Justify Risk
GNPX is a clinical-stage biotech company developing gene therapies for the treatment of cancer and diabetes.
5 Top Penny Stocks To Buy For Under $5 On Webull Today
Are these penny stocks on your Webull watch list? The post 5 Top Penny Stocks To Buy For Under $5 On Webull Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Genprex strengthens leadership team with appointments to newly-created positions of chief medical officer and of chief manufacturing and technology officer
Genprex, Inc. said it has strengthened its leadership team with the appointments of Dr Mark S.
Genprex Strengthens Management Team with Appointments of Industry Leaders Mark S. Berger, M.D.
AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Company has strengthened its leadership team with the appointments of...
Source: https://incomestatements.info
Category: Stock Reports